A liposome containing polydeoxyribonucleotide and its preparation method and application

Abstract

The application provides a liposome containing polydeoxyribonucleotide and a preparation method and application thereof. Components of the liposome include polydeoxyribonucleotide, polypeptide, hydrogenated lecithin, cholesterol, methoxypolyethylene glycol and water. The polydeoxyribonucleotide in the liposome of the application can remove skin surface layer free radicals from the root, inhibit epidermal microinflammatory reaction and repair damaged keratinocytes; the polypeptide can synergistically enhance the efficacy of the polydeoxyribonucleotide and neutralize skin inflammatory mediators; the hydrogenated lecithin and cholesterol form a phospholipid bilayer liposome similar to the skin structure, improve the compatibility of active substances, promote the deep transdermal absorption of the polydeoxyribonucleotide and the polypeptide; the methoxypolyethylene glycol modifies the outer layer of the liposome, reduces the degradation of the liposome by skin surface layer substances, prolongs the action time and improves the stability; and the five components can cooperate with each other to make the product have mild and long-lasting antioxidant and anti-inflammatory soothing effects.

Description

Technical Field

[0001] This invention belongs to the field of daily cosmetics technology, specifically relating to a liposome containing polydeoxyribonucleotides, its preparation method, and its application. Background Technology

[0002] Oxidative stress and epidermal inflammation are two key skin problems that modern cosmetic research focuses on addressing. These two factors are highly coupled in the skin's microenvironment, forming a vicious cycle of positive feedback, and are the fundamental external causes of various sub-healthy skin conditions and skin aging. Under normal physiological conditions, the human skin surface has a natural antioxidant barrier, maintaining a dynamic balance between the generation of epidermal free radicals and the skin's own clearance capacity. However, with increased external environmental stimulation and daily skin damage, common triggers in beauty scenarios such as ultraviolet radiation, air pollution, blue light radiation, excessive cleansing, contact with irritating cosmetic ingredients, and irregular sleep patterns directly lead to an excessive accumulation of free radicals in the skin. Excessive free radicals damage the lipid structure of the stratum corneum, degrade collagen and elastin in the dermis, and damage the organelle structure of epidermal cells, causing lipid peroxidation, weakened skin barrier, and premature aging of epidermal cells. Simultaneously, the oxidative stress response on the skin surface stimulates the activation of keratinocytes and innate immune cells, inducing a low-grade inflammatory response in the epidermis, triggering skin problems such as redness, burning, sensitivity, and micro-inflammatory infiltration.

[0003] Micro-inflammation of the skin further induces epidermal cells to secrete large amounts of reactive oxygen species, continuously amplifying the oxidative damage effect on the skin and forming a vicious cycle of skin oxidation and epidermal micro-inflammation. This leads to problems such as photoaging, skin sensitivity, redness and intolerance, dryness, itching and peeling, pigmentation, enlarged pores, collagen loss and relaxation, and barrier damage. At the same time, long-term superficial low-grade inflammation and oxidative damage are also key factors in causing stubborn pigmentation, premature true wrinkles, and recurrent allergic dermatitis. Therefore, products with multiple functions such as clearing skin free radicals, repairing the skin's antioxidant barrier, soothing epidermal micro-inflammation, and stabilizing the skin's microecology are the core research and development focus in the cosmetics industry.

[0004] CN121818493A discloses an anti-inflammatory, soothing, and repairing composition and its preparation method. The composition is formulated from witch hazel extract, cactus extract, oat bran extract, ophiopogon root extract, scutellaria baicalensis stem and leaf extract, and oat β-glucan in specific mass proportions; wherein the scutellaria baicalensis stem and leaf extract is prepared by a fermentation process combined with water extraction using a complex of Lactobacillus pentosus and Lactobacillus casei. This composition possesses excellent anti-inflammatory, soothing, and skin barrier repair effects, making it suitable for preparing various skincare products. It has high compatibility with sensitive and problem skin types and broad application prospects. This invention also provides a method for preparing an anti-inflammatory, soothing, and repairing serum containing this composition; the process is simple, gentle, and easily industrialized.

[0005] CN121129673A discloses a skincare composition with soothing, repairing, and antioxidant functions, comprising the following components by weight percentage: 0.38–1.5% soothing and anti-inflammatory complex, 2.2–4.8% barrier repair complex, 0.35–1.45% antioxidant complex, 1.0–9.8% moisturizer, 1.5–5% emulsifier, 0.2–0.7% thickener, 1–6% silicone oil conditioning agent, 0.9–1.8% preservative, 0.03–0.08% chelating agent, 0.05–0.2% pH adjuster, and the balance being water. This invention possesses soothing, anti-inflammatory, skin barrier repair, and antioxidant functions, and also exhibits excellent skincare effects for sensitive skin and early signs of aging.

[0006] Currently, most mainstream antioxidant and anti-inflammatory soothing skincare products on the market only possess the ability to scavenge surface free radicals, failing to soothe micro-inflammation of the skin's surface; or they offer rapid anti-inflammatory effects but lack skin antioxidant and barrier repair capabilities, making it difficult to achieve long-term skin stability. Therefore, there is an urgent need for a product that is highly adaptable, safe, non-irritating, and combines antioxidant, anti-inflammatory, and soothing properties to meet consumer needs. Summary of the Invention

[0007] To address the shortcomings of existing technologies, this invention provides a liposome containing polydeoxyribonucleotides, its preparation method, and its applications.

[0008] To achieve this objective, the present invention employs the following technical solution: In a first aspect, the present invention provides a liposome containing polydeoxyribonucleotides, wherein the components of the liposome include polydeoxyribonucleotides, polypeptides, hydrogenated lecithin, cholesterol, methoxy polyethylene glycol and water.

[0009] The polydeoxyribonucleotides (PDRN) in the liposomes of this invention can eliminate free radicals on the skin surface, inhibit epidermal micro-inflammatory responses, and repair damaged keratinocytes at the source. The peptides synergistically amplify the efficacy of PDRN, neutralize skin inflammatory mediators, strengthen the antioxidant and repair capabilities of the dermis, and improve skin redness and dullness caused by inflammation. Hydrogenated lecithin and cholesterol, as auxiliary raw materials for liposome formation, can improve the biocompatibility of the formulation, promote the transdermal penetration of PDRN and peptides, and reduce the irritation of active ingredients. Simultaneously, they stabilize the skin barrier and reduce oxidative inflammatory damage induced by external stimuli. Methoxylated polyethylene glycol, as a functional modifying excipient, mainly plays a role in stabilizing the formulation, shielding against acidic and alkaline environmental interference, inhibiting the degradation and inactivation of PDRN in the cosmetic system, and prolonging the retention time of active ingredients on the skin surface. The formulation selected in this invention addresses the shortcomings of PDRN alone, such as weak efficacy, poor stability, and poor transdermal absorption. The five components are mutually compatible and synergistic, working together to exert a more significant antioxidant, anti-inflammatory, and soothing effect.

[0010] Preferably, the components of the liposome containing polydeoxyribonucleotides include, by weight, 20-30 parts polydeoxyribonucleotides, 2-8 parts polypeptides, 30-50 parts hydrogenated lecithin, 15-20 parts cholesterol, 10-15 parts methoxy polyethylene glycol, and 200-500 parts water.

[0011] The amount of polydeoxyribonucleotide added in the liposomes containing polydeoxyribonucleotides of the present invention can be 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts or 29 parts, etc. The amount of the polypeptide added can be 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, or 7.5 parts, etc.; The amount of hydrogenated lecithin added can be 31 parts, 33 parts, 35 parts, 38 parts, 40 parts, 42 parts, 45 parts, 47 parts, or 49 parts, etc. The amount of cholesterol added can be 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, 18.5 parts, 19 parts, or 19.5 parts, etc.; The amount of methoxy polyethylene glycol added can be 10.5 parts, 11 parts, 11.5 parts, 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts, or 14.5 parts, etc. The amount of water added can be 210 parts, 230 parts, 250 parts, 280 parts, 300 parts, 310 parts, 330 parts, 350 parts, 380 parts, 400 parts, 420 parts, 450 parts, 470 parts, or 490 parts, etc.

[0012] Preferably, the polydeoxyribonucleotide includes animal polydeoxyribonucleotides and / or plant polydeoxyribonucleotides.

[0013] Preferably, the polydeoxyribonucleotide includes animal polydeoxyribonucleotides and plant polydeoxyribonucleotides.

[0014] Preferably, the mass ratio of the animal polydeoxyribonucleotide to the plant polydeoxyribonucleotide is 1:(0.3-1.5), for example, it can be 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3 or 1:1.4, etc.

[0015] Preferably, the animal polydeoxyribonucleotides include salmon polydeoxyribonucleotides and / or rainbow trout polydeoxyribonucleotides.

[0016] Preferably, the animal polydeoxyribonucleotide is salmon polydeoxyribonucleotide.

[0017] Preferably, the plant polydeoxyribonucleotide includes ginseng polydeoxyribonucleotide and / or rose polydeoxyribonucleotide.

[0018] Preferably, the plant polydeoxyribonucleotide is ginseng polydeoxyribonucleotide.

[0019] Preferably, the salmon polydeoxyribonucleotide has a molecular weight of 200-600 bp, for example, 250 bp, 300 bp, 350 bp, 400 bp, 450 bp, 500 bp or 550 bp.

[0020] Preferably, the molecular weight of the ginseng polydeoxyribonucleotide is 50-150 bp, for example, it can be 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, 110 bp, 120 bp, 130 bp or 140 bp.

[0021] The salmon PDRN (polydeoxyribonucleotide) has a 98% base similarity to human DNA, exhibiting excellent biocompatibility. It promotes fibroblast proliferation and collagen synthesis through activation via adenosine A2A receptors. The ginseng PDRN promotes skin regeneration and barrier improvement, upregulates filaggrin expression, and promotes the proliferation of keratinocytes and fibroblasts. This invention utilizes the molecular weight difference between the two PDRN sources to construct a layered action system. The salmon PDRN (longer fragment, 200-600 bp) is responsible for structural repair in the deep dermis, providing a lasting ECM (extracellular matrix) remodeling signal, promoting type I and type III collagen synthesis, and improving skin elasticity and thickness. The ginseng PDRN (shorter fragment, 50-150 bp) is responsible for rapid penetration and repair of the epidermis and superficial dermis. The smaller fragment penetrates the stratum corneum more easily, rapidly activating keratinocyte migration and accelerating barrier repair. The combination of these two PDRNs synergistically enhances the product's antioxidant, anti-inflammatory, repairing, and soothing effects.

[0022] Preferably, the polypeptide comprises any one or a combination of at least two of oligopeptide-4, tetrapeptide-1, acetyl tetrapeptide-5, acetyl hexapeptide-8, or tripeptide-1 copper.

[0023] Preferably, the polypeptide is a combination of oligopeptide-4, tetrapeptide-1, and acetyltetrapeptide-5.

[0024] As a preferred embodiment of the present invention, the oligopeptide-4 can inhibit the release of inflammatory factors and reduce skin redness and discomfort; the tetrapeptide-1 can scavenge free radicals and weaken skin damage caused by oxidative stress; and the acetyl tetrapeptide-5 can soothe sensitive skin and reduce skin stress response. The three work together to block inflammatory pathways and reduce free radical accumulation, thus relieving redness, dryness, and itching. Compared to single peptides, the antioxidant, anti-inflammatory, and soothing effects are significantly enhanced.

[0025] Preferably, the mass ratio of oligopeptide-4, tetrapeptide-1 and acetyl tetrapeptide-5 is (2-4):(1-2):(1-2).

[0026] "2-4" can be 2.1, 2.3, 2.5, 2.8, 3, 3.2, 3.5, 3.7, or 3.9, etc. The first "1-2" can be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9, etc.; The second "1-2" can be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 or 1.9, etc.

[0027] Preferably, the liposomes containing polydeoxyribonucleotides further include excipient stabilizers; Preferably, the liposomes containing polydeoxyribonucleotides further include 1-5 parts of excipient stabilizer by weight, for example, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts or 4.5 parts, etc.

[0028] Preferably, the excipient stabilizer includes mannitol and / or trehalose.

[0029] Preferably, the excipient stabilizer is mannitol and trehalose.

[0030] Preferably, the mass ratio of mannitol to trehalose is 1:(0.5-1.5), for example, it can be 1:0.6, 1:0.8, 1:1, 1:1.2 or 1:1.4, etc.

[0031] In a second aspect, the present invention provides a method for preparing liposomes containing polydeoxyribonucleotides according to the first aspect, the method comprising: Polydeoxyribonucleotides, polypeptides, hydrogenated lecithin, cholesterol, and methoxy polyethylene glycol are mixed in water to obtain a mixture. The mixture is then homogenized by low-temperature microfluidic jet to obtain the liposomes containing polydeoxyribonucleotides.

[0032] Preferably, the mixing process further includes the addition of a shaping stabilizer.

[0033] Preferably, the specific steps of the low-temperature microfluidic homogenization include: (1) Homogenize the mixture at 20-30℃ (e.g., 21℃, 23℃, 25℃, 27℃ or 29℃, etc.) and 300-500 bar (e.g., 350 bar, 400 bar or 450 bar, etc.) for 20-30s (e.g., 21s, 23s, 25s, 27s or 29s, etc.); (2) Then cool the mixture to -5 to 0℃ (e.g., -1℃, -2℃, -3℃ or -4℃, etc.) and freeze for 10 to 15 min (e.g., 11 min, 12 min, 13 min or 14 min). (3) Homogenize the mixture after step (2) at 20-30℃ (e.g., 21℃, 23℃, 25℃, 27℃ or 29℃, etc.) and 500-800 bar (550 bar, 600 bar, 650 bar, 700 bar or 750 bar, etc.) for 20-30s (e.g., 21s, 23s, 25s, 27s or 29s, etc.). (4) Cool the mixture after step (2) to -5-0℃ (e.g., -1℃, -2℃, -3℃ or -4℃, etc.), freeze for 10-15 min (e.g., 11 min, 12 min, 13 min or 14 min), and then let the mixture stand and filter to obtain the liposome containing polydeoxyribonucleotides.

[0034] Preferably, the homogenization cycle in step (1) is repeated 2-4 times (e.g., 2, 3 or 4 times, etc.), with an interval of 55-65s between each homogenization (e.g., 56s, 58s, 60s, 62s or 64s, etc.).

[0035] Preferably, the homogenization cycle in step (3) is repeated 2-4 times (e.g., 2, 3 or 4 times, etc.), with an interval of 85-95s between each homogenization (e.g., 86s, 88s, 90s, 92s or 94s, etc.).

[0036] Preferably, the pore size of the filter in step (4) is 0.2-0.3 μm, for example, it can be 0.22 μm, 0.24 μm, 0.26 μm or 0.28 μm.

[0037] Thirdly, the present invention provides the application of liposomes containing polydeoxyribonucleotides as described in the first aspect in the preparation of cosmetics.

[0038] Preferably, the cosmetic product includes any one of a face mask, face cream, lotion, or serum.

[0039] All the specific point values ​​within the above range can be selected, and will not be elaborated on here.

[0040] Compared with the prior art, the present invention has the following beneficial effects: In this invention, hydrogenated lecithin and cholesterol form a phospholipid bilayer liposome similar to the skin structure, enhancing the compatibility of active ingredients and promoting the deep transdermal absorption of PDRN and peptides. The outer layer of the liposome is modified with methoxy polyethylene glycol, reducing the degradation of liposomes by substances on the skin surface, prolonging the duration of action, and improving stability. The five components work together to alleviate the problem of active ingredient inactivation, providing sustained release, and thus giving the product a mild and long-lasting antioxidant, anti-inflammatory, and soothing effect. Detailed Implementation

[0041] The technical solution of the present invention will be further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as limiting the invention in any way.

[0042] The sources of some of the raw materials used in the embodiments or comparative examples of this invention are shown in Table 1 below: Table 1 All other raw materials can be used as long as they are purchased from authorized distributors.

[0043] Examples 1-3 The embodiments provide three types of liposomes containing polydeoxyribonucleotides. The components of the polydeoxyribonucleotide-containing liposomes are shown in Table 2 below. The amounts of each component in the table are parts. Table 2 The method for preparing the polydeoxyribonucleotide-containing liposomes in Example 1 is as follows: (1) Polydeoxyribonucleotides, polypeptides, hydrogenated lecithin, cholesterol and methoxy polyethylene glycol are mixed in water to obtain a mixture; (2) Homogenize the mixture at 25°C and 400 bar for 25 seconds. Repeat the homogenization process three times, with an interval of 60 seconds between each cycle. (3) Then cool the mixture after step (2) to -3°C and freeze for 15 min; (4) Homogenize the mixture after step (3) at 30°C and 700 bar for 20 seconds. Repeat the homogenization process 4 times with an interval of 90 seconds between each cycle. (4) Cool the mixture after step (3) to -5°C, freeze for 10 min, then let the mixture stand for 2 h, and filter through a 0.22 μm filter membrane to obtain the liposome containing polydeoxyribonucleotides.

[0044] The liposome preparation methods of Examples 2 and 3 are the same as those of Example 1.

[0045] Example 4 This embodiment provides a liposome containing polydeoxyribonucleotides. The only difference between this embodiment and Example 1 is that the liposome does not include salmon polydeoxyribonucleotides in the composition. The reduced amount of ginseng polydeoxyribonucleotides is used to make up the difference. The remaining components and amounts are the same as in Example 1. The preparation method is the same as in Example 1.

[0046] Example 5 This embodiment provides a liposome containing polydeoxyribonucleotides. The only difference between this embodiment and Example 1 is that the liposome does not include ginseng polydeoxyribonucleotides in the composition. The reduced amount of salmon polydeoxyribonucleotides is used to make up the difference. The remaining components and amounts are the same as in Example 1. The preparation method is the same as in Example 1.

[0047] Example 6 This embodiment provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that salmon polydeoxyribonucleotides are 24 parts and ginseng polydeoxyribonucleotides are 2 parts. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0048] Example 7 This embodiment provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that salmon polydeoxyribonucleotides are 10 parts and ginseng polydeoxyribonucleotides are 16 parts. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0049] Example 8 This embodiment provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not include oligopeptide-4 in the components. The reduction is made up by tetrapeptide-1 and acetyl tetrapeptide-5 in proportion. The remaining components and addition amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0050] Example 9 This embodiment provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not include tetrapeptide-1 in the components. The reduction is made up by oligopeptide-4 and acetyl tetrapeptide-5 in proportion. The remaining components and addition amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0051] Example 10 This embodiment provides a polydeoxyribonucleotide liposome, which differs from Example 1 only in that it does not include acetyl tetrapeptide-5 in the components. The reduction is made up by oligopeptide-4 and tetrapeptide-1 in proportion. The remaining components and the amount added are the same as in Example 1, and the preparation method is the same as in Example 1.

[0052] Comparative Example 1 This comparative example provides a liposome that differs from Example 1 only in that it does not include salmon polydeoxyribonucleotide and ginseng polydeoxyribonucleotide in its components. The reduction is made up by oligopeptide-4, tetrapeptide-1 and acetyl tetrapeptide-5 in proportion to the number of parts. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0053] Comparative Example 2 This comparative example provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not include polypeptides (oligopeptide-4, tetrapeptide-1 and acetyl tetrapeptide-5) in its components. The reduction is made up by salmon polydeoxyribonucleotides and ginseng polydeoxyribonucleotides in proportion to each other. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0054] Comparative Example 3 This comparative example provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not include hydrogenated lecithin in its components. The reduction is made up by cholesterol and methoxy polyethylene glycol in proportion. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0055] Comparative Example 4 This comparative example provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not contain cholesterol. The reduction is made up by hydrogenated lecithin and methoxy polyethylene glycol in proportion. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0056] Comparative Example 5 This comparative example provides a liposome containing polydeoxyribonucleotides, which differs from Example 1 only in that it does not include methoxy polyethylene glycol in its components. The reduction is made up by hydrogenated lecithin and cholesterol in proportion. The remaining components and amounts are the same as in Example 1, and the preparation method is the same as in Example 1.

[0057] Test Example 1: Antioxidant Efficacy Study – DPPH Free Radical Scavenging Experiment Test subjects: Samples from Examples 1-10 and Comparative Examples 1-5 Test method: Take 1 g of product, add 2 mL of anhydrous ethanol, dissolve completely, then add 2 mL of 60 μmol / L DPPH solution and mix well. Let stand for 30 min, zero the instrument with anhydrous ethanol, and measure the absorbance at 517 nm as Ai. In the same way, take 2 mL of anhydrous ethanol solvent + 2 mL of DPPH solution, mix well and measure the absorbance as Ac. Take another 1 g of product, dissolve it, add 2 mL of anhydrous ethanol, then add 2 mL of anhydrous ethanol solvent, mix well and measure the absorbance as Aj.

[0058] Calculate its free radical scavenging rate using the following formula.

[0059] Clearance rate (%) = [1 - (Ai - Aj) / Ac] × 100% Where Aj represents the contribution of the sample itself to the absorbance; Ai represents the absorbance of the sample after the DPPH treatment; and Ac represents the absorption of DPPH itself at the measurement wavelength.

[0060] The higher the DPPH scavenging rate, the stronger the antioxidant capacity of the composition to scavenge free radicals. The results are shown in Table 3 (each sample was measured in parallel 5 times, and the data are presented as average values).

[0061] Table 3 The results in Table 3 show that the liposomes containing polydeoxyribonucleotides involved in this invention have a good DPPH scavenging effect. The polydeoxyribonucleotides and peptides promote each other in terms of antioxidant efficacy, and have an unexpected synergistic effect. Furthermore, the choice of polydeoxyribonucleotides and peptides also affects the antioxidant effect.

[0062] Test Example 2: Anti-inflammatory efficacy test Test subjects: Samples from Examples 1-10 and Comparative Examples 1-5 Test method: (1) Dilute the well-cultured Raw264.7 cells to a concentration of 1×10⁻⁶. 5 cfu / mL; (2) Prepare a 12-well cell plate and fill it with a concentration of 1×10⁻⁶ cells. 5 Raw264.7 cells at cfu / mL were pipetted into 12-well plates, 1 mL per well, and incubated at 37°C for 24 h. (3) The experiment consisted of 21 groups: blank group (no sample added), LPS group (1 μg / mL LPS added), experimental group (samples of Examples 1-10 and Comparative Examples 1-5 with 1 μg / mL LPS at a concentration of 2 mg / mL), and positive control group (0.1 mg / mL dexamethasone added). The supernatant of Raw264.7 cell culture medium was discarded, and the corresponding solution for each group was added. The cells were cultured at 37°C for 24 h. (4) Centrifuge the supernatant and detect the concentrations of inflammatory factors TNF-α and IL-6 according to the test steps on the ELISA kit. Each group was measured in parallel 5 times and the average value was taken.

[0063] The results are shown in Table 4: Table 4 As shown in Table 4, the liposomes involved in this invention have a very significant inhibitory effect on inflammatory factors TNF-α and IL-6. Among them, salmon polydeoxyribonucleic acid and ginseng polydeoxyribonucleic acid have a synergistic effect in inhibiting Propionibacterium acnes. When hydrogenated lecithin, cholesterol and methoxy polyethylene glycol are present in the formula, the product has a better inhibitory effect on inflammatory factors.

[0064] Test Example 3, Stability Test The stability of the samples obtained in Examples 1-3 was evaluated: (1) Cold resistance stability: Each group of samples was subjected to a cold resistance test. The cold resistance test was conducted by placing the samples at -15℃ for 24 h and then restoring them to room temperature (25℃). The phenomena of the samples were observed. (2) Centrifugal stability: Centrifuge each group of samples at 2000 r / min and room temperature (25℃) for 30 min and observe the phenomenon of the sample. (3) High temperature stability: Each group of samples was subjected to a high temperature test. After being placed at 48℃ for 24 h, the samples were placed at -10℃ for 1 h and then restored to room temperature (25℃). The phenomenon of the sample was observed.

[0065] The results are shown in Table 5.

[0066] Table 5 As shown in Table 5, the product involved in this invention has good cold resistance, centrifugal stability and high temperature stability.

[0067] Test Example 4: Safety Evaluation The specific method was as follows: Forty women aged 18-35 years with no history of allergies were selected. Each subject used samples prepared in Examples 1-10. After cleaning the subject's arm, the patch applicator containing the sample was applied to the selected location on the arm using non-irritating adhesive tape. After application, the patch was gently pressed with the fingers to ensure even application to the skin, and left on for 48 hours. During these 48 hours, the subject kept the patch area dry and avoided strenuous exercise, scratching, and prolonged sun exposure. After 48 hours, the applicator was removed and marked. After 30 minutes, once the indentation disappeared, the sample was evaluated under sufficient light.

[0068] The grading criteria for adverse skin reactions are shown in Table 6: Table 6 The results are shown in Table 7: Table 7 As shown in Table 7, no adverse skin reactions were observed in the volunteers after the spot tester was removed. This indicates that the raw materials used in this invention are safe and non-irritating, and have no adverse effects on the human body after interaction, demonstrating high safety.

[0069] The applicant declares that the technical solution of this invention is illustrated by the above embodiments, but this invention is not limited to the above embodiments, that is, it does not mean that this invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of raw materials for the products of this invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of this invention.

[0070] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0071] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. A liposome containing polydeoxyribonucleotides, characterized in that, The liposomes are composed of polydeoxyribonucleotides, polypeptides, hydrogenated lecithin, cholesterol, methoxy polyethylene glycol, and water.

2. The liposome containing polydeoxyribonucleotides according to claim 1, characterized in that, The components of the liposome containing polydeoxyribonucleotides, by weight, include 20-30 parts polydeoxyribonucleotides, 2-8 parts polypeptides, 30-50 parts hydrogenated lecithin, 15-20 parts cholesterol, 10-15 parts methoxy polyethylene glycol, and 200-500 parts water.

3. The liposomes containing polydeoxyribonucleotides according to claim 1 or 2, characterized in that, The polydeoxyribonucleotides include animal polydeoxyribonucleotides and / or plant polydeoxyribonucleotides; Preferably, the polydeoxyribonucleotide includes animal polydeoxyribonucleotides and plant polydeoxyribonucleotides; Preferably, the mass ratio of the animal polydeoxyribonucleotide to the plant polydeoxyribonucleotide is 1:(0.3-1.5).

4. The liposome containing polydeoxyribonucleotides according to claim 3, characterized in that, The animal polydeoxyribonucleotides include salmon polydeoxyribonucleotides and / or rainbow trout polydeoxyribonucleotides; Preferably, the animal polydeoxyribonucleotide is salmon polydeoxyribonucleotide; Preferably, the plant polydeoxyribonucleotide includes ginseng polydeoxyribonucleotide and / or rose polydeoxyribonucleotide; Preferably, the plant polydeoxyribonucleotide is ginseng polydeoxyribonucleotide.

5. The liposome containing polydeoxyribonucleotides according to any one of claims 1-4, characterized in that, The polypeptide includes any one or a combination of at least two of oligopeptide-4, tetrapeptide-1, acetyl tetrapeptide-5, acetyl hexapeptide-8 or tripeptide-1 copper. Preferably, the polypeptide is a combination of oligopeptide-4, tetrapeptide-1, and acetyltetrapeptide-5.

6. The liposome containing polydeoxyribonucleotides according to any one of claims 1-5, characterized in that, The liposomes containing polydeoxyribonucleotides also include excipient stabilizers; Preferably, the liposomes containing polydeoxyribonucleotides further include 1-5 parts by weight of excipient stabilizer; Preferably, the excipient stabilizer includes mannitol and / or trehalose.

7. A method for preparing liposomes containing polydeoxyribonucleotides according to any one of claims 1-6, characterized in that, The preparation method includes: Polydeoxyribonucleotides, polypeptides, hydrogenated lecithin, cholesterol, and methoxy polyethylene glycol are mixed in water to obtain a mixture. The mixture is then homogenized by low-temperature microfluidic jet to obtain the liposomes containing polydeoxyribonucleotides.

8. The preparation method according to claim 7, characterized in that, The mixing process also includes the addition of a shape stabilizer; Preferably, the specific steps of the low-temperature microfluidic homogenization include: (1) Homogenize the mixture at 20-30℃ and 300-500 bar for 20-30s; (2) Then cool the mixture to -5 to 0°C and freeze for 10 to 15 minutes; (3) Homogenize the mixture after step (2) at 20-30℃ and 500-800 bar for 20-30s; (4) Cool the mixture after step (2) to -5-0℃, freeze for 10-15 min, and then let the mixture stand and filter to obtain the liposome containing polydeoxyribonucleotides.

9. The preparation method according to claim 8, characterized in that, The homogenization cycle described in step (1) is repeated 2-4 times, with an interval of 55-65 seconds between each homogenization. Preferably, the homogenization cycle in step (3) is repeated 2-4 times, with an interval of 85-95 seconds between each homogenization cycle; Preferably, the pore size of the filter in step (4) is 0.2-0.3 μm.

10. The use of a liposome containing polydeoxyribonucleotides according to any one of claims 1-6 in the preparation of cosmetics.

Images